New research suggests combining GLP-1 medications like Wegovy with menopausal hormone therapy (MHT) may support better weight loss and heart health in postmenopausal women—but it’s no magic fix.
A 2024 study in Menopause found that women using both MHT and the GLP-1 drug semaglutide lost about 16% of their body weight in a year, compared to 12% with the drug alone. Experts say MHT might help reverse menopause-related metabolic changes and improve sleep, which indirectly supports weight loss.
However, doctors caution that MHT isn’t for everyone, especially those with severe obesity or heart disease. Risks include blood clots and heart attacks. That’s why GLP-1 therapy alone may be a safer first step for high-risk patients.
Cardiovascular benefits are also promising. Women on GLP-1s showed improved A1C and blood pressure. Those also on MHT had better cholesterol levels, too.
Still, there’s a lack of long-term research. It’s unclear whether weight lost is mostly fat or muscle—making resistance training essential. A recent study shows resistance training boosts lean mass in women aged 40–60, reinforcing its role in any weight loss plan.
Experts stress this combo is not a one-size-fits-all solution. Doctors should assess individual risk before recommending both therapies.
Bottom line: GLP-1s and MHT might work better together—but they’re not a cure-all. Talk to your doctor about personal risks and safer ways to manage menopause weight.
Read More:
- Weight Loss After Menopause 5 Surprise Foods To Avoid
- How Does Amberen Help With Weight Loss?
- AI Advances Early Detection of Postpartum Mental Health Risks
